HCM
MRNS

Harvey Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Harvey Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,500
Closed -$53K – 75
2016
Q1 		$53K Sell
2,500
-1,000
-29% -$21.2K 0.03% 76
2015
Q4 		$106K Sell
3,500
-2,875
-45% -$84.3K 0.04% 80
2015
Q3 		$212K Buy
6,375
+2,625
+70% +$148K 0.08% 80
2015
Q2 		$174K Hold
3,750
– – 0.06% 87
2015
Q1 		$134K Buy
+3,750
New +$165K 0.05% 80

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Harvey Capital Management's MRNS Position: Q2 2016 in Review

Harvey Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2016, closing a stake of 2,500 shares — an estimated $53K sold.

Harvey Capital Management first reported a position in MRNS in Q1 2015 and held it in 5 quarters. The position peaked at $212K in Q3 2015. 28 funds tracked by Wall St. Rank hold MRNS as of Q2 2016.

  • Harvey Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
  • Harvey Capital Management sold 2,500 Marinus Pharmaceuticals, Inc shares in Q2 2016, an estimated $53K.
  • Harvey Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2015 and held it in 5 quarters.
  • Harvey Capital Management's Marinus Pharmaceuticals, Inc position peaked at $212K in Q3 2015.
  • 28 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2016.

Based on Harvey Capital Management's 13F filing for Q2 2016, filed 21 Jul 2016.